A Phase 2 interventional study of Nivolumab and IDO1 Inhibitor BMS-986205 in Lip, Oral Cavity Squamous Cell Carcinoma and Pharynx, sponsored by Thomas Jefferson University. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Thomas Jefferson University · Phase 2, Interventional, and Treatment
How we know · 7 judgments
Study was terminated early due to toxicity concerns by the Sponsor.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 15th largest by enrollment, is one of 10 that started in 2019, is one of 27 in phase 2, and was the 23rd registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
Mayo Clinic · Sites in United States
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 7
First in 2014; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 44 across the 46 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 46 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 3 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
5 of the studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03576417Phase 3Groupe Oncologie Radiotherapie Tete et CouA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | 2027-08 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT03406247Gustave Roussy, Cancer Campus, Grand ParisAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. BMS986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab with BMS986205 may work better than nivolumab alone in treating patients with squamous cell cancer of the head and neck.
PRIMARY OBJECTIVES:
I. To assess the impact of IDO1 inhibitor BMS-986205 (BMS986205) and nivolumab versus nivolumab alone on tumor radiographic response both at the primary tumor site and in regional lymph nodes by investigator assessment at 5 weeks.
SECONDARY OBJECTIVES:
I. To investigate whether adding the IDO1 - inhibitor, BMS986205, to nivolumab therapy affects intratumoral and systemic anti-tumor immunity.
II. To assess the impact of BMS986205 and nivolumab verses nivolumab alone on pathologic treatment effect bother at the primary and regional lymph nodes.
III. To determine the effect of BMS986205 and nivolumab versus nivolumab alone on immune cell composition within the tumor microenvironment including the presence of effector T cells (Teff), regulatory T cells (Treg), and tumor-associated macrophages (TAM).
IV. To further characterize the effect of BMS986205 when combined with nivolumab on kynurenine production and correlate these levels with effects on immune cell composition and polarization.
V. To review the relationship of p16 status by immunohistochemistry with immune cell polarization, tumor radiographic response, and immune cell composition.
VI. To review the relationship of PD-L1 status by immunohistochemistry with immune cell polarization, tumor radiographic response, and immune cell composition.
VII. To assess the safety and tolerability of BMS986205 and nivolumab. VIII. Evaluate surgical wound healing post treatment.
EXPLORATORY OBJECTIVES:
I. To further characterize the effect of BMS986205 and nivolumab versus nivolumab alone through analysis of T cell repertoire.
II. To assess the interactions between the immune and metabolic microenvironment through analysis of alterations in exosome composition in peripheral blood as it related to immune, cytokine and metabolic alterations before, during and after treatment.
III. To identify risks for poor physical and mental health outcomes; examine bio-behavioral factors associated with cancer treatment outcomes; and evaluate the physical and psychosocial needs of cancer survivors through patient reported outcomes.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive IDO1 inhibitor BMS-986205 orally (PO) once daily (QD). Beginning week 2, patients also receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.
ARM II: Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.
After completion of study treatment, patients are followed up periodically for 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males who are sexually active with WOCBP must agree to use a condom during any sexual activity for the duration of treatment with study treatment plus 7 months after the last dose of the study treatment (i.e., 90 days [duration of sperm turnover] plus the time required for nivolumab to undergo approximately 5 half-lives). This criterion applies to azoospermic males as well. In addition, male participants must be willing to refrain from sperm donation during this time.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days. Nivolumab is administered as a 480mg intravenous (IV) infusion once every 4 weeks. BMS986205 is administered orally at a dose of 100 mg once daily.
Biological: Nivolumab · Biological: IDO1 Inhibitor BMS-986205 · Procedure: Therapeutic Conventional Surgery · Other: Questionnaire Administration
Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days. Nivolumab is administered as a 480mg intravenous (IV) infusion once every 4 weeks.
Biological: Nivolumab · Procedure: Therapeutic Conventional Surgery · Other: Questionnaire Administration
Data from Contemporaneous Study 10237 (NCT03238365) participants who received Nivolumab alone prior to surgery is used as a historical controls under the current window of treatment (WOT), to bolster the control group. Nivolumab was administered as a 240mg intravenous (IV) infusion every 2 weeks for 2 doses over a 4-week treatment period prior to surgical resection.
Given IV
Also known as: 946414-94-4, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Given PO
Also known as: (R)-N-(4-chlorophenyl)-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propenamide, BMS 986205, BMS-986205, BMS986205, IDO-1 Inhibitor BMS-986205, Indoleamine-pyrrole 2,3-Dioxygenase Inhibitor BMS-986205, ONO-7701
Undergo Surgery
Ancillary studies
Objective Response
Radiographic response was assessed at the primary site and involved lymph nodes. Participants with ≥10% volumetric reduction at either site and no progression received a second treatment cycle before surgery, while those with stable disease or progression proceeded to surgery at the 5-week evaluation. The study hypothesized that adding an IDO inhibitor to PD-1 blockade would improve radiographic response. The primary endpoint was the proportion of participants eligible for a second cycle. The 10% cutoff was based on prior publications showing that volumetric analysis is more sensitive than single-axis RECIST v1.1 and allows minor immune-related increases (0-9%) while defining \>10% growth as progression.
Time frame: At 5 weeks
Objective Pathologic Response at Time of Surgery
Pathologic specimens were independently graded by two pathologists as outlined in our previous publication (2). The entire mass or surgical specimen (in the event of a partial/ complete response) was sectioned to calculate the pTR. Criteria for response included evidence of macrophage reaction, multinucleated giant cells and granulomas, fibrosis adjacent to residual tumor nests. In complete responders where no more viable tumor was identified, alteration of the normal tissue architecture by fibrosis and macrophage reaction was used to identify areas of previously viable malignancy. Tumors with pTR of ≥20% were defined as responders (R), while those with pTR \<20% were defined as minimal or non-responders (NR) at the primary site and Lymph Nodes (LNs).
Time frame: At time of surgery
Change in Immune Cell Polarization (Th1/Th2; M1/M2) in Peripheral Blood and Tumor Specimens
Will be analyzed and compared using multiplex cytokine analysis collected before and after exposure to nivolumab +/- IDO1 inhibitor BMS-986205 (BMS986205). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
Time frame: Baseline up to 12 months
Change in Inflammatory Markers
These include soluble (s)CD40 ligand (L), EGF, eotaxin, FGF-2, Flt-3 ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF), granulocyte colony-macrophage (GM)-CSF, GRO, IFN-alpha2, IL-1alpha, IL-1beta, IL-1ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12 (p40), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1alpha, MIP-1beta, PDGF-AA, PDGF-AB/BB, RANTES, TGF-alpha, TNF-alpha, VEGF. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%
Time frame: Baseline up to 12 months
Change in Prevalence of Intratumoral Immune Cell Populations (Effector T Cells [Teff], Regulatory T Cells [Treg], and Tumor-associated Macrophages [TAM] in Patients Treated With Nivolumab and BMS986205 as Compared to Patients Treated With Nivolumab Alone
Assessed by immunohistochemistry (IHC). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
Time frame: Baseline up to 12 months
Localization of Immune Cells Within the Tumor
Will be analyzed using confocal microscopy.
Time frame: Up to 12 months
Multiplex Colocalization of Resident Immune Cells
Will utilize 5-6 markers per section.
Time frame: Up to 12 months
Ratio of Tryptophan to Kynurenine
Tryptophan and kynurenine concentrations were measured in plasma samples using validated assays. The outcome is expressed as the ratio of tryptophan to kynurenine, a marker of IDO1 activity. Results are reported as median values with full range (minimum to maximum) across participants
Time frame: Up to 12 months
Intratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function in Human Papilloma Virus (HPV) + and HPV- Tumors
Baseline IHC staining for P16 will be performed as a surrogate for HPV status. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
Time frame: Up to 12 months
Intratumoral Immune Cell Populations, Immune Polarization Data, Exosome Composition, and Exosome Function Relative to PD-L1 Expression Levels
Assessed by IHC. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
Time frame: Up to 12 months
Number of Immune Related Adverse Events
Number of immune related adverse events. Adverse Events will be graded by Common Terminology Criteria for Adverse Events version 5.0.
Time frame: Up to 100 days
Intratumoral T-cell Receptor (TCR) Repertoire and Diversity
Assesses with next generation sequencing.
Time frame: Up to 12 months
Change in Exosome Abundance and Composition in the Peripheral Blood of Patients Both Before and After Exposure to Both Nivolumab and BMS986205 and Nivolumab Alone
Will be compared between treatment arms using two-sample t-tests.
Time frame: Baseline up to 12 months
Number of Participants With Wound Dehiscence
Number of Participants with wound dehiscence, postop wound infection (requiring antibiotics), and fistula formation
Time frame: Up to 12 months
Changes in Tumor Volume and Rates of Radiographic Response
Will be summarized by treatment arm and compared using two-sample t-tests or Fisher's exact test, as appropriate.
Time frame: Baseline up to 12 months
Patient-reported Outcomes
Data will be collected and correlated to both immune cell composition and polarization and tumor radiographic response using scores from Patient Health Questionnaire (PHQ)2/9, Functional Assessment of Cancer Therapy- General (FACT-G), and FACT-head and neck (HN). Will conduct descriptive statistics and will summarize variable of interest using standard statistics such as frequency tables, means, and standard deviations. All measures will be evaluated for reliability and factor analyses will be conducted.
Time frame: Up to 12 months
| Milestone | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Started | 31 | 11 | 23 |
| Completed | 27 | 11 | 19 |
| Not completed | 4 | 0 | 4 |
| Withdrew: Withdrawal by subject | 4 | 0 | 3 |
| Withdrew: Death | 0 | 0 | 1 |
Radiographic response was assessed at the primary site and involved lymph nodes. Participants with ≥10% volumetric reduction at either site and no progression received a second treatment cycle before surgery, while those with stable disease or progression proceeded to surgery at the 5-week evaluation. The study hypothesized that adding an IDO inhibitor to PD-1 blockade would improve radiographic response. The primary endpoint was the proportion of participants eligible for a second cycle. The 10% cutoff was based on prior publications showing that volumetric analysis is more sensitive than single-axis RECIST v1.1 and allows minor immune-related increases (0-9%) while defining \>10% growth as progression.
| Participants | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Radiographic Responders | 13 | 4 | 10 |
| Radiographic Non-Responders | 14 | 7 | 9 |
Pathologic specimens were independently graded by two pathologists as outlined in our previous publication (2). The entire mass or surgical specimen (in the event of a partial/ complete response) was sectioned to calculate the pTR. Criteria for response included evidence of macrophage reaction, multinucleated giant cells and granulomas, fibrosis adjacent to residual tumor nests. In complete responders where no more viable tumor was identified, alteration of the normal tissue architecture by fibrosis and macrophage reaction was used to identify areas of previously viable malignancy. Tumors with pTR of ≥20% were defined as responders (R), while those with pTR \<20% were defined as minimal or non-responders (NR) at the primary site and Lymph Nodes (LNs).
| Participants | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Responders | 16 | 6 | — |
| Non-Responders | 11 | 5 | — |
Will be analyzed and compared using multiplex cytokine analysis collected before and after exposure to nivolumab +/- IDO1 inhibitor BMS-986205 (BMS986205). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
No measurements were reported for this outcome.
These include soluble (s)CD40 ligand (L), EGF, eotaxin, FGF-2, Flt-3 ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF), granulocyte colony-macrophage (GM)-CSF, GRO, IFN-alpha2, IL-1alpha, IL-1beta, IL-1ra, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12 (p40), IL-13, IL-15, IL-17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1alpha, MIP-1beta, PDGF-AA, PDGF-AB/BB, RANTES, TGF-alpha, TNF-alpha, VEGF. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%
No measurements were reported for this outcome.
Assessed by immunohistochemistry (IHC). If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
No measurements were reported for this outcome.
Will be analyzed using confocal microscopy.
No measurements were reported for this outcome.
Will utilize 5-6 markers per section.
No measurements were reported for this outcome.
Tryptophan and kynurenine concentrations were measured in plasma samples using validated assays. The outcome is expressed as the ratio of tryptophan to kynurenine, a marker of IDO1 activity. Results are reported as median values with full range (minimum to maximum) across participants
| Ratio of Tryptophan to Kynurenine | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Pre-Kynurenine Responders | 0.5 (-1 to 1.8) | -0.1 (-1.4 to 0.65) | — |
| Pre-Kynurenine Non-Responders | -0.2 (-1.3 to 1) | 0 (-1.2 to 0.8) | — |
Baseline IHC staining for P16 will be performed as a surrogate for HPV status. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
No measurements were reported for this outcome.
Assessed by IHC. If there is at least one significant difference between groups among the primary outcomes, the two randomization arms will be compared with respect to each secondary outcome using two-sample t-tests. P-values for comparisons of changes in secondary outcomes will be adjusted using the method of Benjamini and Hochberg to control the FDR among the secondary outcomes at 5%.
No measurements were reported for this outcome.
Number of immune related adverse events. Adverse Events will be graded by Common Terminology Criteria for Adverse Events version 5.0.
| Adverse Events | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Number of Immune Related Adverse Events | 14 | 2 | 15 |
Assesses with next generation sequencing.
No measurements were reported for this outcome.
Will be compared between treatment arms using two-sample t-tests.
No measurements were reported for this outcome.
Number of Participants with wound dehiscence, postop wound infection (requiring antibiotics), and fistula formation
| Participants | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Number of Participants With Wound Dehiscence | 0 | 0 | 2 |
Will be summarized by treatment arm and compared using two-sample t-tests or Fisher's exact test, as appropriate.
No measurements were reported for this outcome.
Data will be collected and correlated to both immune cell composition and polarization and tumor radiographic response using scores from Patient Health Questionnaire (PHQ)2/9, Functional Assessment of Cancer Therapy- General (FACT-G), and FACT-head and neck (HN). Will conduct descriptive statistics and will summarize variable of interest using standard statistics such as frequency tables, means, and standard deviations. All measures will be evaluated for reliability and factor analyses will be conducted.
No measurements were reported for this outcome.
Collected over Adverse event reporting will begin after study treatment, unless the AE/SAE is caused by a study specific screening procedure, and continue until 100 days (for non-serious AEs) or 100 days (for SAEs) after the last day of study participation. Up to 14 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: BMS986205 + Nivolumab | 0/31 (0%) | 6/31 (19.4%) | 30/31 (96.8%) |
| Arm B: Group I - Nivolumab Only | 0/11 (0%) | 1/11 (9.1%) | 11/11 (100%) |
| Arm C: Group II - Nivolumab Only | 1/23 (4.3%) | 1/23 (4.3%) | 13/23 (56.5%) |
| Event | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/31 | 1/11 | 0/23 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/31 | 0/11 | 0/23 |
| Endocrine disorders - Other, specifyEndocrine disorders | 0/31 | 0/11 | 1/23 |
| DeathGeneral disorders | 0/31 | 0/11 | 1/23 |
| AspirationRespiratory, thoracic and mediastinal disorders | 1/31 | 0/11 | 0/23 |
| ConfusionPsychiatric disorders | 1/31 | 0/11 | 0/23 |
| Respiratory, thoracic and mediastinal disorders - Other, specifyRespiratory, thoracic and mediastinal disorders | 1/31 | 0/11 | 0/23 |
| Investigations - Other, specifyInvestigations | 1/31 | 0/11 | 0/23 |
| HematomaVascular disorders | 1/31 | 0/11 | 0/23 |
| HypokalemiaMetabolism and nutrition disorders | 1/31 | 0/11 | 0/23 |
| Event | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only |
|---|---|---|---|
| DysphagiaGastrointestinal disorders | 21/31 | 8/11 | 0/23 |
| FatigueGeneral disorders | 16/31 | 7/11 | 0/23 |
| Pain - OralGastrointestinal disorders | 9/31 | 5/11 | 0/23 |
| Sore ThroatRespiratory, thoracic and mediastinal disorders | 13/31 | 5/11 | 0/23 |
| Weight LossInvestigations | 9/31 | 5/11 | 0/23 |
| RashSkin and subcutaneous tissue disorders | 1/31 | 1/11 | 9/23 |
| Dry MouthGastrointestinal disorders | 7/31 | 4/11 | 0/23 |
| HoarsenessRespiratory, thoracic and mediastinal disorders | 11/31 | 2/11 | 0/23 |
| NauseaGastrointestinal disorders | 10/31 | 0/11 | 0/23 |
| ConstipationGastrointestinal disorders | 9/31 | 2/11 | 0/23 |
| Age, Categorical(Participants) | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 6 | 12 | 37 |
| >=65 years | 12 | 5 | 7 | 24 |
| Sex: Female, Male(Participants) | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only | Total |
|---|---|---|---|---|
| Female | 8 | 3 | 1 | 12 |
| Male | 23 | 8 | 18 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 29 | 11 | 18 | 58 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 | 4 |
| White | 28 | 11 | 16 | 55 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 | 2 |
| Region of Enrollment(participants) | Arm A: BMS986205 + Nivolumab | Arm B: Group I - Nivolumab Only | Arm C: Group II - Nivolumab Only | Total |
|---|---|---|---|---|
| United States | 31 | 11 | 19 | 61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Feb 2022, 34 months.
Results were first posted in Oct 2026, 4 years 8 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Dec 2025 → Feb 2022 and completion Dec 2025 → Mar 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study was terminated early due to toxicity concerns by the Sponsor.
Study was terminated early due to toxicity concerns by the Sponsor.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Linrodostat
Squamous Cell Carcinoma of Head and Neck →